Table 1 Characteristics of patients with previous COVID-19 infection according to vaccination status.
From: Breakthrough infections in MPN-COVID vaccinated patients
Total pts with previous infection | UNVACCINATED | VACCINATED | p | |
|---|---|---|---|---|
N = 418 | N = 131 | N = 287 | ||
Male gender | 189/418 (45.2%) | 51/131 (38.9%) | 138/287 (48.1%) | 0.081 |
Age | 61.3 (53.0–71.7) | 59.3 (47.9–71.9) | 61.8 (54.6–71.7) | 0.016 |
> 70 | 124/417 (29.7%) | 36/131 (27.5%) | 88/286 (30.8%) | 0.50 |
BMI | 24.0 (21.3–26.5) | 24.4 (21.7–26.1) | 23.9 (21.3–26.5) | 0.89 |
MPN diagnosis | ||||
ET | 156/418 (37.3%) | 41/131 (31.3%) | 115/287 (40.1%) | 0.085 |
PV | 133/418 (31.8%) | 41/131 (31.3%) | 92/287 (32.1%) | 0.88 |
MF | 90/418 (21.5%) | 37/131 (28.2%) | 53/287 (18.5%) | 0.024 |
Early/pre-PMF | 39/418 (9.3%) | 12/131 (9.2%) | 27/287 (9.4%) | 0.94 |
Previous thrombosis | 81/415 (19.5%) | 24/129 (18.6%) | 57/286 (19.9%) | 0.75 |
Mutational status | ||||
JAK2 V617F | 303/408 (74.3%) | 93/127 (73.2%) | 210/281 (74.7%) | 0.75 |
CALR | 64/231 (27.7%) | 19/89 (21.3%) | 45/142 (31.7%) | 0.087 |
MPL | 10/220 (4.5%) | 5/88 (5.7%) | 5/132 (3.8%) | 0.53 |
JAK2 EXON12 | 1/126 (0.8%) | 1/55 (1.8%) | 0/71 (0.0%) | 0.44 |
Spleen palpable | ||||
No | 270/386 (69.9%) | 88/125 (70.4%) | 182/261 (69.7%) | |
Yes | 111/386 (28.8%) | 35/125 (28.0%) | 76/261 (29.1%) | 0.87 |
Previously splenectomized | 5/386 (1.3%) | 2/125 (1.6%) | 3/261 (1.1%) | |
Size below costal margin (cm) | 4.0 (2.0–6.0) | 4.5 (2.0–6.5) | 3.0 (2.0–6.0) | 0.30 |
MPN treatment post-COVID | ||||
Phlebotomy | 76/410 (18.5%) | 24/130 (18.5%) | 52/280 (18.6%) | 0.98 |
Cytoreduction | 289/418 (69.1%) | 83/131 (63.4%) | 206/287 (71.8%) | 0.084 |
HU | 196/412 (47.6%) | 54/130 (41.5%) | 142/282 (50.4%) | 0.096 |
Anagrelide | 13/412 (3.2%) | 1/130 (0.8%) | 12/282 (4.3%) | 0.071 |
Interferon | 12/412 (2.9%) | 3/130 (2.3%) | 9/282 (3.2%) | 0.76 |
Ruxolitinib | 63/412 (15.3%) | 20/130 (15.4%) | 43/282 (15.2%) | 0.97 |
Antiplatelets post-COVID | 250/410 (61.0%) | 75/129 (58.1%) | 175/281 (62.3%) | 0.43 |
ASA | 233/412 (56.6%) | 73/130 (56.2%) | 160/282 (56.7%) | 0.91 |
Anticoagulants | 95/409 (23.2%) | 32/128 (25.0%) | 63/281 (22.4%) | 0.57 |
Characteristics of COVID-19 | ||||
Wave | ||||
1 (Wild-type) | 94/418 (22.5%) | 14/131 (10.7%) | 80/287 (27.9%) | <0.001 |
2 (Alpha, Beta, Gamma) | 284/418 (67.9%) | 83/131 (63.4%) | 201/287 (70.0%) | 0.175 |
3 (Delta) | 19/418 (4.5%) | 17/131 (13.0%) | 2/287 (0.7%) | <0.001 |
4 (Omicron) | 21/418 (5.0%) | 17/131 (13.0%) | 4/287 (1.4%) | <0.001 |
COVID-19 severitya | ||||
Asymptomatic infection | 16/389 (4.1%) | 9/123 (7.3%) | 7/266 (2.6%) | 0.003 |
Mild Illness | 286/389 (73.5%) | 84/123 (68.3%) | 202/266 (75.9%) | 0.11 |
Moderate Illness | 25/389 (6.4%) | 7/123 (5.7%) | 18/266 (6.8%) | 0.69 |
Severe/critical Illness | 62/389 (15.9%) | 23/123 (18.7%) | 39/266 (14.7%) | 0.31 |
Vaccine information | ||||
Months since prior infection | – | – | 5.9 (4.3–11.2) | – |
No administered doses | ||||
Only 1 dose | – | – | 109/287 (38.0%) | – |
2 doses | – | – | 112/287 (39.0%) | – |
3–4 doses | – | – | 66/287 (23.0%) | – |
Vaccine type | ||||
Pfizer/BioNTech | – | – | 204/287 (71.1%) | – |
Moderna | – | – | 53/287 (18.5%) | – |
AstraZeneca | – | – | 12/287 (4.2%) | – |
Johnson&Johnson | – | – | 3/287 (1.0%) | – |
NA | – | – | 15/287 (5.2%) | – |
Reinfections | 18 (4.3%) | 8 (6.1%) | 10 (3.5%) | 0.22 |
Months to reinfection from prior COVID-19 | 13.1 (8.2–15.0) | 7.5 (4.8–13.1) | 14.3 (12.9–16.8) | 0.016 |
Months to reinfection from last vaccine dose | – | – | 3.1 (2.5–7.1) | – |
Number of doses | ||||
Only 1 dose | – | – | 2/10 (20.0%) | |
2 doses | – | – | 4/10 (40.0%) | – |
3–4 doses | – | – | 4/10 (40.0%) | |
Wave of reinfection | ||||
3 (Delta) | 4/18 (22.2%) | 3/8 (37.5%) | 1/10 (10.0%) | 0.27 |
4 (Omicron) | 14/18 (77.8%) | 5/8 (62.5%) | 9/10 (90.0%) | |
COVID-19 severitya | ||||
Asymptomatic infection | 2/17 (11.8%) | 1/8 (12.5%) | 1/9 (11.1%) | 0.72 |
Mild Illness | 13/17 (76.5%) | 7/8 (87.5%) | 6/9 (66.7%) | |
Severe/critical Illness | 2/17 (11.8%) | 0/8 (0.0%) | 2/9 (22.2%) | |
Patient disposition | ||||
Home-treated | 16/18 (88.9%) | 8/8 (100.0%) | 8/10 (80.0%) | 0.48 |
Hospitalized | 2/18 (11.1%) | 0/8 (0.0%) | 2/10 (20.0%) | |
Respiratory support | 1/18 (5.6%) | 0/8 (0.0%) | 1/10 (10.0%) | 1.00 |
ICU | 1/18 (5.6%) | 0/8 (0.0%) | 1/10 (10.0%) | 1.00 |
Symptoms | ||||
Fever | 5/18 (27.8%) | 3/8 (37.5%) | 2/10 (20.0%) | 0.61 |
Cough | 7/18 (38.9%) | 1/8 (12.5%) | 6/10 (60.0%) | 0.066 |
Dyspnea | 3/18 (16.7%) | 0/8 (0.0%) | 3/10 (30.0%) | 0.22 |
Systemic | 1/18 (5.6%) | 0/8 (0.0%) | 1/10 (10.0%) | 1.00 |
Gastrointestinal | 1/18 (5.6%) | 0/8 (0.0%) | 1/10 (10.0%) | 1.00 |
Fatigue | 6/18 (33.3%) | 2/8 (25.0%) | 4/10 (40.0%) | 0.64 |
Outcome reinfections | ||||
Deathb | 1/18 (5.6%) | 0/8 (0.0%) | 1/10 (10.0%) | 1.00 |
